JDD February 2023 Issue Highlights
The February issue of the Journal of Drugs in Dermatology (JDD) includes the perfect blend of original articles, case reports, and brief communications exploring topics such as efficacy and safety of 1% clascoterone cream in patients aged ≥12 years with acne vulgaris, dupilumab’s impact on atopic dermatitis among adolescent and adult patients, development and validation of a photonumeric scale …
The February issue of the Journal of Drugs in Dermatology (JDD) includes the perfect blend of original articles, case reports, and brief communications exploring topics such as efficacy and safety of 1% clascoterone cream in patients aged ≥12 years with acne vulgaris, dupilumab’s impact on atopic dermatitis among adolescent and adult patients, development and validation of a photonumeric scale … 
Wow! The ODAC Dermatology Conference in January 2022 highlighted the importance of conference attendance and the need for expert lectures on clinically relevant dermatologic topics. We are in an era when basic sciences and translational research has direct correlation and impact on our therapeutic measures for patients. While it is refreshing to have so many options for patients’ treatment, it … 
Atopic dermatitis is a heterogeneous, chronic inflammatory disease that affects upwards of 10% of children and 7% of adults in the United States. Despite being an incredibly common skin concern among patients, AD continues to pose diagnostic and treatment challenges to dermatologists.
What are some common misconceptions about AD?
AD always starts in childhood. FALSE. 25% of adults w … 
The March 2022 issue of the Journal of Drugs in Dermatology (JDD) includes the perfect blend of original articles, case reports, and editorials. With topics ranging from acne and psoriasis to Platelet Rich Plasma (PRP) for scarring alopecia and racial differences and their impact on treatment for hidradenitis suppurativa, we share this month’s issue highlights straight from the JDD Editor’s de … 
Chromate causes persistent, difficult to treat irritant and allergic contact dermatitis in cement-handling occupational workers. When therapeutics such as topical corticosteroids, topical calcineurin inhibitors, phototherapy and immune-modulating treatments like methotrexate fail, many patients are advised that avoidance may be the only remaining option – an option that may be particularly chall …